Dicerna Pharmaceuticals Financial Statements (DRNA)
|
|
|
|
Report date
|
|
|
30.03.2017 |
08.03.2018 |
13.03.2019 |
28.02.2020 |
26.02.2021 |
|
09.11.2021 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.295 |
2.28 |
6.18 |
23.9 |
164.3 |
|
192.9 |
|
Operating Income, bln rub |
|
|
-59.7 |
-60.6 |
-61.2 |
-128.2 |
-113.2 |
|
-121.3 |
|
EBITDA, bln rub |
? |
|
-58.7 |
-59.3 |
-87.5 |
-119.2 |
-110.5 |
|
-118.5 |
|
Net profit, bln rub |
? |
|
-59.5 |
-60.0 |
-88.9 |
-120.5 |
-112.7 |
|
-124.4 |
|
|
OCF, bln rub |
? |
|
-48.7 |
-45.3 |
18.3 |
-0.692 |
175.1 |
|
21.1 |
|
CAPEX, bln rub |
? |
|
0.449 |
0.133 |
0.359 |
6.35 |
11.7 |
|
12.5 |
|
FCF, bln rub |
? |
|
-49.2 |
-45.5 |
17.9 |
-7.04 |
163.4 |
|
8.56 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
60.0 |
62.9 |
67.4 |
152.1 |
277.5 |
|
314.1 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
R&D, bln rub |
|
|
41.7 |
37.0 |
45.7 |
109.3 |
205.4 |
|
227.4 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.603 |
0.003 |
0.020 |
|
0.012 |
|
|
Assets, bln rub |
|
|
51.3 |
120.9 |
409.0 |
597.4 |
707.8 |
|
772.1 |
|
Net Assets, bln rub |
? |
|
41.2 |
101.2 |
200.7 |
152.2 |
137.8 |
|
107.7 |
|
Debt, bln rub |
|
|
0.000 |
0.000 |
0.000 |
23.5 |
52.2 |
|
64.4 |
|
Cash, bln rub |
|
|
45.9 |
113.7 |
302.6 |
348.9 |
568.8 |
|
565.5 |
|
Net debt, bln rub |
|
|
-45.9 |
-113.7 |
-302.6 |
-325.4 |
-516.7 |
|
-501.1 |
|
|
Ordinary share price, rub |
|
|
2.88 |
9.03 |
10.7 |
22.0 |
22.0 |
|
38.0 |
|
Number of ordinary shares, mln |
|
|
20.7 |
20.7 |
55.6 |
68.4 |
74.5 |
|
77.7 |
|
|
Market cap, bln rub |
|
|
60 |
187 |
595 |
1 507 |
1 642 |
|
2 951 |
|
EV, bln rub |
? |
|
14 |
73 |
292 |
1 182 |
1 125 |
|
2 450 |
|
Book value, bln rub |
|
|
41 |
101 |
201 |
152 |
138 |
|
108 |
|
|
EPS, rub |
? |
|
-2.87 |
-2.90 |
-1.60 |
-1.76 |
-1.51 |
|
-1.60 |
|
FCF/share, rub |
|
|
-2.37 |
-2.19 |
0.32 |
-0.10 |
2.19 |
|
0.11 |
|
BV/share, rub |
|
|
1.99 |
4.89 |
3.61 |
2.22 |
1.85 |
|
1.38 |
|
|
EBITDA margin, % |
? |
|
-19 889% |
-2 603% |
-1 416% |
-498.7% |
-67.3% |
|
-61.5% |
|
Net margin, % |
? |
|
-20 174% |
-2 637% |
-1 439% |
-503.9% |
-68.6% |
|
-64.5% |
|
FCF yield, % |
? |
|
-82.4% |
-24.3% |
3.02% |
-0.47% |
9.95% |
|
0.29% |
|
ROE, % |
? |
|
-144.4% |
-59.3% |
-44.3% |
-79.1% |
-81.8% |
|
-115.6% |
|
ROA, % |
? |
|
-116.1% |
-49.7% |
-21.7% |
-20.2% |
-15.9% |
|
-16.1% |
|
|
P/E |
? |
|
-1.00 |
-3.12 |
-6.69 |
-12.5 |
-14.6 |
|
-23.7 |
|
P/FCF |
|
|
-1.21 |
-4.12 |
33.1 |
-214.1 |
10.0 |
|
344.9 |
|
P/S |
? |
|
202.3 |
82.2 |
96.3 |
63.1 |
9.99 |
|
15.3 |
|
P/BV |
? |
|
1.45 |
1.85 |
2.96 |
9.90 |
11.9 |
|
27.4 |
|
EV/EBITDA |
? |
|
-0.24 |
-1.24 |
-3.34 |
-9.92 |
-10.2 |
|
-20.7 |
|
Debt/EBITDA |
|
|
0.78 |
1.92 |
3.46 |
2.73 |
4.68 |
|
4.23 |
|
|
R&D/CAPEX, % |
|
|
9 286% |
27 807% |
12 733% |
1 722% |
1 748% |
|
1 820% |
|
|
CAPEX/Revenue, % |
|
|
152.2% |
5.84% |
5.81% |
26.6% |
7.15% |
|
6.48% |
|
| Dicerna Pharmaceuticals shareholders |
